1 research outputs found
Recommended from our members
Refractory Pediatric Autoimmune Enteropathy Successfully Treated with Hematopoietic Stem Cell Transplant
Both allogeneic and autologous hematopoietic stem cell transplant (HSCT) have utility in refractory autoimmune diseases. We report a pediatric case of autoimmune enteropathy (AIE) that was successfully treated with haploidentical SCT and post-transplant cyclophosphamide.
A 4 year old male with chronic diarrhea, multiple food allergies, eczema, recurrent infections, failure to thrive and TPN dependence was diagnosed as AIE with biopsy proven anti-enterocyte antibodies. Immune evaluation revealed no mutation for immunodysregulation polyendocrinopathy enteropathy X-linked and cytotoxic T-lymphocyte-associated protein 4 sequencing. T cell function and primary immunodeficiency panel were normal. He failed conventional treatments with TNF blockade, calcineurin inhibitors, mTOR inhibitors, and costimulatory blockade (abatacept). A haplo-HSCT was performed with rituximab 375 mg/m2 day (D) -14, fludarabine 150 mg/m2 D -11 to D -7, thiotepa 10 mg/kg D -7, melphalan 140 mg/m2 D -6, Thymoglobulin 10 mg/kg D -5 to D -2, along with post-transplant cyclophosphamide 100 mg/kg D +3 to D +4.
The patient engrafted on D +16 with neutrophils above 500 mcL on three consecutive CBCs, and he was platelet transfusion independent after D+19 to maintain platelets above 50,000 mcL. He resumed regular diet on day + 46 post haplo-HSCT without any gastrointestinal symptoms and is gaining weight at the time of this report. Post-transplant course was complicated by grade II acute skin graft versus host disease that responded to prednisolone and tacrolimus, and HHV6 reactivation which resolved after starting ganciclovir.
This is a case of a pediatric patient with refractory AIE who is now asymptomatic post haplo-HSCT after failing treatment with extensive immune modulators. This treatment may prove to be helpful for similar challenging patients with AIE